



Sue Lau, Pharm.D Infectious Disease Pharmacist Orlando Health – Dr P Philips Hospital 21<sup>st</sup> September, 2017

### **Disclosure:**

• I have no financial conflict of interest to report

### **Program Outlines:**

- Evaluate the importance of an Antimicrobial Stewardship Program (ASP)
- Apply the steps of building up an ASP from scratch with limited resources
- Identify ways to sustain the ASP
- Show the accomplishments from the ASP at Dr. P. Phillips Hospital

# Why We Care?

- Global antimicrobial resistance is happening!
  - In 2001, only 1 state reported a case of carbapenem-resistant enterobacteriaceae (CRE) vs. only 2 states without CRE in early 2015
  - Multi-drug resistant organisms (MDRO) cause at least 2 millions infection / year and ~23,000 death in U.S.
- About 50% antibiotics used in the inpatient setting are unnecessary
- Antibiotics are the most common cause of adverse drug events
- Improving antibiotic prescribing can reduce patent HARM

# Importance of Antimicrobial Stewardship:

- All antimicrobial use, appropriate or not, carries a risk for developing resistance.
- Antimicrobials should be use judiciously and prescribed only when recommended
  - Use the Right drug, dose, and duration
- Antimicrobial stewardship efforts are critical to limit the development of antibiotic resistance





#### FORUM ON ANTIBIOTIC STEWARDSHIP

JUNE 2, 2015



#### **National Action Plan Goals:**

- 1. Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections.
- 2. Strengthen National One-Health Surveillance Efforts to Combat Resistance.
- 3. Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria.
- 4. Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines
- Improve International Collaboration and Capacities for Antibiotic-resistance Prevention, Surveillance, Control, and Antibiotic Research and Development.

# Joint Commission / CMS Regulations



Official Publication of Joint Commission Requirements

#### **New Antimicrobial Stewardship Standard**

APPLICABLE TO HOSPITALS AND CRITICAL ACCESS HOSPITALS

Effective January 1, 2017

Medication Management (MM)

#### Standard MM.09.01.01

The [critical access] hospital has an antimicrobial stewardship program based on current scientific literature.

#### Elements of Performance for MM09.01.01

 Leaders establish antimicrobial stewardship as an organizational priority. (See also LD.01.03.01, EP 5)

**Note:** Examples of leadership commitment to an antimicrobial stewardship program are as follows:

- Accountability documents
- Budget plans

- Infection prevention plans
- Performance improvement plans
- Strategic plans
- Using the electronic health record to collect antimicrobial stewardship data
- 2. The [critical access] hospital educates staff and licensed independent practitioners involved in antimicrobial ordering, dispensing, administration, and monitoring about antimicrobial resistance and antimicrobial stewardship practices. Education occurs upon hire or granting of initial privileges and periodically thereafter, based on organizational need.
- 3. The [critical access] hospital educates patients, and their families as needed, regarding the appropriate use of antimicrobial medications, including antibiotics. (For more information on patient education, refer to Stan-

Continued on page 4



Building an Antimicrobial Stewardship

Program (ASP) from scratch...


# Dr. P. Phillips Hospital (DPH)

- Located in Southwest Orlando in Central Florida
- Community Hospital
- 237 acute care beds medical & surgical facility
- Not for-profit organization
- Adult population
- Part of Orlando Health
  - Orlando Regional Medical Center (ORMC)
  - UF Health Cancer Center (UFHCC)
  - Winnie Palmer Hospital (WPH)
  - Arnold Palmer Hospital (APH)
  - South Seminole Hospital (SSH)
  - Health Central Hospital (HCH)
  - South Lake Hospital (SLH)



### Prior to the ASP

- DPH was the highest in term of the antimicrobial utilization and cost at Orlando Health (OH):
  - Meropenem, linezolid, daptomycin, tigecycline... etc
- The antibiotic Cost / Patient Day Equivalent (PDE):
  - \$33.6 at DPH vs. \$22.9 at ORMC
- The usage of meropenem was above the national average



# **ASP** in Dr. P. Phillips Hospital

- Started in fiscal year 2010
- ID trained pharmacist (1 FTE) plus an enthusiastic ID physician (0 FTE)
- Goals / Mission:
  - > Ensuring the proper use of antimicrobials:
    - To optimize patient outcomes
    - To reduce adverse drug events including secondary infection
    - To prevent or slow the emergence of antimicrobial resistance
    - To promote cost-effectiveness regimen



# Limited Resources... Toughest Moment .......


- Limited ID pharmacist role (>50% staffing)
- No antibiotic restriction (failed in the past)
- No electronic chart system (paper notes → hard to read ⊗)
- No software, IS reports.....
- Low antimicrobial susceptibility Antibiogram
  - Antibiogram had not been done for years
- Big Drug Rep influence
- Challenging physicians:
  - 4 private ID physician groups
  - Private hospitalist groups: switching patients everyday
  - Physicians were not taking their responsibilities on antibiotics
  - Intensivists using broad spectrum & NEW abx no streamlining
  - Surgeons using tigecycline, meropenem for surgical prophylaxis
- Commonly seen pts on prolonged abx course for no reason

### **Overview ASP Duties:**

#### Daily antimicrobial agents monitoring & surveillance:

- Review all C.diff positive cases
- Review all patients on antimicrobials:
  - IV to PO switch
  - Bug-drug Mismatch
  - Possibility de-escalation per culture results
  - Decrease the duration of antimicrobials
  - Formulary alternatives per culture results, allergies, pharmacotherapy
  - Dose optimization per renal / hepatic function
  - Discontinue surgical prophylaxis antimicrobial agent(s)
  - Allergies investigation (Antimicrobial Allergy Team)
  - Monitor high cost / broad spectrum / high toxicity / national shortage agents:
    - Meropenem, tigecycline, linezolid, daptomycin, colistin, aminoglycosides, ampho-B

### **Establish Local ASP Subcommittee:**



Bonus: Adm Rep, Epidemiologist

# **Low Hanging Fruits:**




#### Implement Pharmacy Protocols:

- Mandatory Vancomycin, Aminoglycosides, and Colistin / Polymyxin B Dosing pharmacy consult protocol
  - Education pharmacy staff for proper dosing
- IV to PO Pharmacy protocol
  - Antibiotics with high bioavailability (e.g. metronidazole, ciprofloxacin)
- Automatic post-op antibiotic protocol (core measure)
- Antimicrobial renal dosing adjustment protocol
- Advocate alternative dosing with B- lactams extended infusion:
  - Piperacillin- tazobactam 4 hours infusion Protocol
  - Nafcillin continuous infusion

### **Low Hanging Fruits:**

### Reduction of Inappropriate Antimicrobial use

- Mandatory Antimicrobial INDICATION:
  - Ensure choosing the proper agents and dosing
- Mandatory Antimicrobial STOP DATE
  - To avoid prolonged duration



# **Handling Overuse Antimicrobials:**

- Can be done without mandatory restriction!
- For example Meropenem:
  - Data collection
  - Comparison with other similar hospitals (apple to apple)
  - Conduct Medication Utilization Evaluation (MUE)

To: DPH Antimicrobial Stewardship Program Subcommittee

From: Suetping Lau, Pharm.D

Re: Meropenem MUE

A review was conducted for all patients who received Meropenem (Mer) at DPH during the month of August through October, 2010.

#### Data Review:

| Month     | Total Mer orders | Total days on Mer | Avg. days on Mer | Range  | # of pt on Mer >10days |
|-----------|------------------|-------------------|------------------|--------|------------------------|
| August    | 36               | 209               | 5.8              | 2-14   | 3                      |
| September | 27               | 169               | 6.3              | 2-12   | 2                      |
| October   | 38               | 226               | 5.9              | 1 - 17 | 7                      |

Prescribing Physician per each Month

|           | ID | Hospitalist | Intensivist | Pulmonologist | Surgeon | GI |
|-----------|----|-------------|-------------|---------------|---------|----|
| August    | 15 | 12          | 6           | 3             | 0       | 0  |
| September | 9  | 9           | 9           | 0             | 0       | 0  |
| October   | 9  | 14          | 12          | 0             | 2       | 1  |

Meropenem indications per Month:


|         | PNA | Sepsis | UTI | Wound | Abd  | Bacteremia | Pancreatitis | Peritonitis | FN | Pre-op | Misc |
|---------|-----|--------|-----|-------|------|------------|--------------|-------------|----|--------|------|
|         |     | _      |     | infx  | infx |            |              |             |    | proph  |      |
| August  | 11  | 7      | 6   | 8     | 1    | 2          | 1            | 0           | 0  | 0      | 0    |
| Sept    | 5   | 4      | 6   | 5     | 0    | 0          | 2            | 3           | 0  | 0      | 2    |
| October | 9   | 8      | 4   | 5     | 3    | 0          | 2            | 1           | 4  | 1      | 1    |



# **Handling Overuse Antimicrobials:**


- Present MUE results to Stewardship meeting, department meetings
- Meet / Educate individual prescribers
- Daily review with all of meropenem orders

#### Meropenem (FY2008-2016)



# **Ex. Handling Overuse Antimicrobials:**

#### **Daptomycin & linezolid Utilization**



# Surveillance of Antimicrobial Usage:


- Monitor progress and efficacy of antimicrobial usage
- Common Methods:
  - Define Daily Dose (DDD)
    - Amount of drug that a typical patient might receive on any day for therapeutic purposes
  - Days of Therapy (DOT)
    - Broadly applicable to a pediatric population
  - Antimicrobial purchased data
    - Easiest data to obtain from pharmacy
    - Administrative favorable (\$\$\$)
    - Cost can be impacted switching from brand to generic, shortage etc

Curr Treat Options Infect Dis. 2014; 6(2): 101-112.

# Surveillance of Antimicrobial Usage:

- Antibiotic consumption estimates vary based on the method of calculation (i.e., DDD versus DOT)
- Which method to pick?
  - Doesn't matter
  - Most important using consistent metric!
    - Monitor its own consumption trends.
    - Time series analyses allow trends to be detected
- How often to do?
  - Depends.....
  - When starting the ASP, quarterly or semi-annually may need
  - Once stabilized ASP, it can be done annually

# Major antimicrobial agent utilization:



22

### **Perform Annual Antibiogram**

- Monitoring the bacterial resistances
- May see improvement from ASP

#### DPH Antimicrobial Susceptibility Report July 2015 to June 2016

Microbiology Laboratory Number: 321-841-5226

|                            | No. Tested | Am picillin <sup>\$55</sup> | Clindam y cin <sup>\$5\$</sup> | Doxycycline <sup>/555</sup> | Daptomycin <sup>555555</sup>      | Gentamicin <sup>\$</sup> | Linez olid <sup>55555</sup>       | Nitrofurantoin <sup>s</sup><br>urine only | Nafcillin <sup>5555</sup>           | Trim eth/Sulfa <sup>5555</sup> | Vancomycin <sup>\$</sup>          |
|----------------------------|------------|-----------------------------|--------------------------------|-----------------------------|-----------------------------------|--------------------------|-----------------------------------|---|-------------------------------------|--------------------------------|-----------------------------------|
| MIC breakpoint, mcg/mL     |            | ≤8°                         | ≤0.5                           | ≤4                          | ≤1 <sup>d</sup> /≤4 <sup>ce</sup> | ≤1                       | ≤4 <sup>de</sup> /≤2 <sup>c</sup> | ≤32                                       | ≤2 <sup>d</sup> /≤0.25 <sup>e</sup> | ≤2/38                          | ≤4 <sup>ce</sup> /≤2 <sup>d</sup> |
| All Staphylococcus aureus  | 338        | -                           | 70                             | 97                          | 100                               | 100 <sup>g</sup>         | 100                               | 100                                       | 59                                  | 97                             | 100                               |
| MRSA                       | 139        | -                           | 60                             | 94                          | 100                               | 100 <sup>g</sup>         | 100                               | 99  | 0                                   | 93                             | 100                               |
| MSSA                       | 199        | -                           | 80                             | 99                          | 100                               | 100 <sup>g</sup>         | 100                               | 100                                       | 100*                                | 100                            | 100                               |
| Staphylococcus epidermidis | 19         | _                           | 60                             | 84                          | 100                               | 95 <sup>g</sup>          | 100                               | 100                                       | 33                                  | _                              | 100                               |
| Enterococcus faecalis      | 110        | 100                         | _                              | 23                          | 100                               | 71 <sup>h</sup>          | 99                                | 99  | _                                   | _                              | 98                                |
| Enterococcus faecium       | 20         | 25                          | -                              | _                           | 100                               | <b>7</b> 9 <sup>h</sup>  | 95                                | 26  | _                                   | _                              | 70                                |

### Data mining software Assistance

- Enhance ASP activities
- Provide Real-Time alerts
- Able to custom report for individuals' needed
- Common Electronic Health Record (HER)s systems:
  - Epic HER
  - Cerner HER
- Clinical Decision Support systems (CDSSs)
  - TheraDoc
  - SafetySurveillor
  - Quality Compass PathFinder
  - Sentri7
  - Medminded
  - Vigilanz

# ASP weekday Surveillance at DPH

- Review daily antimicrobial use in each hospital unit
- Utilization of Vigilanz alerts:
  - Positive blood cultures, positive PCR blood culture, C.diff positive, positive cultures, ordering restricted antibiotic etc

#### Link to alert: https://www.vigilanzportal.com/dpms/Login.aspx?AlertID= 320001@vigilanzcorp.com Sent: Wed 5/11/2016 6:02 AM Lau, Suet-ping Alert Date: 05/11/2016 06:01 Alert/Warning ID: 1233546 Alert Type: Alert Action Expected Date: 05/11/2016 06:01 Link to alert: https://www.vigilanzportal.com/dpms/Login.aspx? AlertID=1233546&Application=ICM&status=P&clientid=320001 Module: ICM Module Name: Dynamic Infection Control Module Priority: High Rule: DPH Pharmacy - Positive Blood Culture by Nanosphere System: VigiLanz Corp

# Antimicrobial Agent Cost Saving at DPH (Before vs. After ASP):

| -16.0% |
|--------|
|        |
| -37.0% |
|        |
| -9%    |
|        |
| -30%   |
|        |

Potential Cost Saving in 4 years: \$2,945,365

# Quality:



→ Ways to Sustain

Antimicrobial Stewardship


Program (ASP)

# **Tracking ASP Related Interventions**

- Job security!
  - Data to show to your boss, ASP meeting
- Review the acceptance and rejection rates
  - Knowing the trends:
    - Any particular providers who usually reject the interventions?
    - Who are those accept the intervention most often
- Track the potential cost saving from ASP
- Track Critical interventions (quality)
  - Reduce length of stay
  - Prevention Adverse Drug Reactions / bad consequences
  - Bug-Drug mismatch




### Overall Intervention Acceptance Rate at DPH



**Overall Acceptance Rate: 96%** 

#### **Critical Interventions:**



### 1st CAUTI Rounds at DPH

- Established the FIRST CAUTI prevention Rounds at DPH with the Infectious Diseases Physician in 2012
  - Weekly rounds with ID physician
  - Educated Staff and family member to remove unnecessary Foley catheter
- Developed electronic CAUTI Progress Note
- Assisted other sites to establish site wide CAUTI rounds
- Transfer the rounding to the unit charge nurse
- Successfully reduced the CAUTI rate at DPH

| Fiscal Year | # of CAUTI |
|-------------|------------|
| 2011        | 25         |
| 2012        | 15         |
| 2013        | 11         |
| 2014        | 3          |
| 2015        | 2          |
| 2016        | 3          |

411 days without CAUTI

# C. Difficile Infection (CDI) Prevention

- Collaborate Infection Preventionist
  - Review all HACDI cases
  - C. diff task force: launched hand-washing Champaign
  - Unit Practice council
- Reduced unnecessary antimicrobial usage
  - Fluoroquinolones restriction at Orlando Health (FY2013)
- Reduced proton pump inhibitor (PPI) usage

| Fiscal Year | # of HACDI |                         |
|-------------|------------|-------------------------|
| 2010        | 53         |                         |
| 2011        | 82         | EIAS to PCR test        |
| 2012        | 64         |                         |
| 2013        | 75         | 42% reduction in a year |
| 2014        | 43         | 42% reduction in a year |
| 2015        | 52 →86     | NSHN criteria changed   |
| 2016        | 61         |                         |



#### Malipu Thepatel We did it: Zero CAUTI for 411 days ORLANDO HEALTH

- Team Members: Suet-ping Lau, Pharm.D Antonio Crespo, MD Roberto Rojas-Diaz, MD
- Infectious Diseases pharmacist

2010 - 2014:

0.45

0.40

0.35

0.30

0.25

0.20

0.15

0.05

0.00

0.41 0.40

- Chief Quality Officer - Infectious Diseases Physician
- Sam Venus, MD - Intensivist Margaret Parr, BSN,RN,CIC - Infection Preventionist



Outcomes:

Graph 1: Number of CAUTI cases from fiscal year

0.27

CAUTI Rate / 1000 pt days

#### Background:

Catheter associated urinary tract infection (CAUTI) is the most common healthcare associated infection (HAI) in the United States. Studies have shown 26% of patient develop bacteriuria after having a urinary catheter for 2-10 days and 25% of those patients would develop CAUTI. Over 560,000 CAUTI cases are reported annually which carries significant morbidity, mortality and cost for the healthcare system.

#### Aim:

To develop targeted strategies for the prevention of CAUTI by limiting the use and duration of urinary catheterization

#### Actions Taken:

The targeted strategies included:

- Established CAUTI prevention rounds in 2011
- Educated staff to remove indwelling urinary catheter and encourage using external condom catheter (Texas catheter)
- Implemented CAUTI bundle in ICU.
- · Established Unit Quality Triads to address unit specific challenges
- · Utilized bladder scanners to asses urinary retention
- · Removed urinary catheter before post-operative day 2 (POD2) or avoided insertion when able
- Mandated an indication for inserting urinary.
- Limited insertion urinary catheter to RN using aseptic technique and sterile equipment



- Rounds conducted weakly on all floors except ICU Educate hospital stating patents, and tenity members to audid / remove indiveting uninary catheter or use external condom catheter Later, move CAUTI rounds to nurses & hospitalists rounds
- Educate at ICU stant to aucid / remove individing urhary catheter or use external condom catheter
  - Urthary catheller check its iduring daily IC II rounds
     Utilize bladder scanners
- Mandalory indication for inserting urinary cashe len Educate all RMs on proper insertion lechnique Only trained Riks can insert urinary catheller imiliurinary carre ler use in post-surplical patients to PO DZ

#### Over 40% reduction of HACDI in a Year ORLANDO HEALTH

Team Members: Suet-ping Lau, Pharm.D Crespo Antonio, MD Margaret Parr, RN, BSN, CIC

- Infectious Diseases pharmacist
- Chief Quality Officer - Infection Preventionist


#### Background:

The incidence of Clostridium difficile infection (CDI) has had a marked increase during the last decade. Because of this, in 2013, the Department of Health & Human Service (HHS) set a 5-year reduction goal of 30%. Healthcare Associated Clostridium difficile infections (HACDI) is associated with increased hospital stay, cost, morbidity, and mortality. The approximate hospital cost of a CDI case ranges from \$9,179 to \$11,456. Despite the establishment of a antimicrobial stewardship program since 2010, our HACDI rate at Dr. P. Phillips Hospital (DPH) was still not under control.

#### Aim:

#### Outcomes:

Graph 1: Antimicrobial utilization from FY 2008 - 2014



Graph 2: Pantoprazole utilization from FY 2011-2014




Table 1: HACDI rate from 2010 to 2014

| Flacal Year | # of HACDI | Rate / 1,000<br>patent dayı | Rem ark s                                    |
|-------------|------------|-----------------------------|--|
| 2010        | 53         | 0.83                        | Changed EIAto<br>PCR testing in<br>Feb. 2010 |
| 2011        | 82         | 1.33                        |  |
| 2012        | 64         | 1.08                        |  |
| 2013        | 75         | 1.34                        |  |
| 2014        | 43         | 0.8                         |  |

#### Summary

lealthcare Associated Clostridium difficile nfections (HACDI) prevention is complex and hallenging. It requires all members of the ealthcare team to work together. After a emendous hospital wide efforts at DPH, we were ble to have a 43% reduction of our HACDI in FY 014 compared to FY2013, exceeding the 5-year oal set by the HHS!



# **Antimicrobial Allergy Team (AAT)**

- AAT established in DPH since October 2011
  - To evaluate patients who develop NEW vancomycin reaction(s) upon admission at DPH
  - Additional Pre-PEN service to evaluate patient who has history of Penicillin allergy

#### Goals:

- Complete patient allergy profile by eliminating invalid antibiotic allergy
- Improve quality of patient care by broadening the antibiotic choices in the future
- Improve the proper ways of administering vancomycin
- Potential cost saving
- Successfully re-challenges Vancomycin/ PCN: 92%

# **Outpatient Antimicrobial Stewardship**

- At least 30% antibiotics used in the outpatient setting are unnecessary
- Education Primary Care provider to promote appropriate prescribing antibiotics in clinics



### Improvement of bacterial resistance:

### **DPH Annual Antibiogram**

| Pseudomona<br>s <i>aeruginosa</i> | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|-----------------------------------|------|------|------|------|------|------|------|------|
| Amikacin                          | 95   | 95   | 96   | 96   | 98   | 98   | 98   | 97   |
| Cefepime                          | 64   | 83   | 85   | 90   | 91   | 89   | 87   | 95   |
| Ciprofloxacin                     | 57   | 71   | 75   | 88   | 80   | 79   | 84   | 91   |
| Pipercillin-<br>Tazobactam        | 75   | 89   | 92   | 92   | 96   | 93   | 94   | 96   |
| Meropenem                         | 64   | 79   | 86   | 89   | 95   | 93   | 96   | 97   |


### Improvement of bacterial resistance:

Rates of Multiple Drug Resistant organisms (MDRO):

| MDRO Rate                      | 2009-<br>2010 | 2010 –<br>2011 | 2011 –<br>2012 | 2012–<br>2013 | 2013-<br>2014  | 2014-<br>2015 | 2015-<br>2016 | 2016-<br>2017 |
|--------------------------------|---------------|----------------|----------------|---------------|----------------|---------------|---------------|---------------|
| MRSA                           | 55%           | 55%            | 50%            | 50%           | 51%            | 46%           | 41%           | 36%           |
| VRE                            | 17%           | 13%            | 19%            | 17%           | 18%            | 14%           | 5.3%          | 5%            |
| ESBL:                          |               |                |                |               |                |               |               |               |
| • E. <i>Coli</i>               | 8%            | 5%             | 6.6%           | 4.5%          | 6.1%           | 8.6%          | 9.5%          | 9.6%          |
| •K. pneumoniae                 | 15%           | 12%            | 9%             | 8.2%          | 4%             | 8.2%          | 11.2%         | 7%            |
| CRE:                           |               |                |                |               |                |               |               |               |
| • KPC                          | 2.4%          | 1.8%           | 1.6%           | 0.6%          | 0.7%           | 1%            | 0             | 0             |
| •MRSA<br>vancomycin<br>MIC ≥ 2 | NA            | 2.5%<br>(N=6)  | 4.5%<br>(N=9)  | 0             | 1.7%<br>(N=3)* | 0             | 0             | 0.9%<br>(N=1) |

<sup>\*:</sup> Labs removed vancomycin MIC 1.5

# Poster Presentation at IHI Dec, 2013



# Summary



- An ASP was successfully created in a community hospital with limited resources
- Culture of antimicrobial stewardship has changed dramatically since the creation of the program
- Support from physicians and hospital leadership with a dedicated ID trained pharmacist are the keys to the success
- Improvement in resistance pattern and in controlling multidrug resistance has been noted
- The program has spread to the entire organization





Sue Lau, Pharm.D
Infectious Disease Pharmacist
Orlando Health – Dr P Philips Hospital
21<sup>st</sup> September, 2017